ABCE1: Aspartate Carrier Enzyme 1 (G6059)

Target Name: ABCE1

NCBI ID: G6059

ABCE1

ABCE1: Aspartate Carrier Enzyme 1

ABCE1 (Aspartic Acid Carrier Enzyme 1) is a gene that encodes a protein known as ABCE1. The protein is a key regulator of aspartate transport in the body, and is involved in the metabolism of a variety of essential amino acids, including aspartic acid, glutamic acid, and alanine. ABCE1 is expressed in most tissues and cells of the body, and is also highly expressed in the brain, where it plays a crucial role in the regulation of neurotransmitter synthesis and release.

The ABCE1 gene has been identified as a potential drug target in the field of neurodegenerative diseases, due to its involvement in the regulation of aspartate transport and its expression in the brain. Studies have shown that ABCE1 is implicated in the development and progression of a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, overexpression of ABCE1 has been shown to exacerbate the symptoms of these diseases, further supporting its potential as a drug target.

Drugs that target ABCE1 have the potential to treat a variety of neurodegenerative diseases, by inhibiting the activity of this enzyme and improving the levels of aspartate in the brain. This could lead to a reduction in the symptoms of these diseases, and potentially even a reversal of the disease progression.

Overview of ABCE1

ABCE1 is a member of the Aspartate Carrier Transporter (ASCT) family, which is responsible for transporting aspartate across the blood-brain barrier and maintaining the levels of this essential amino acid in the brain. The ASCT family consists of four subfamilies, including ABC, BCX, ASC, and ASG. ABCE1 belongs to the ABC subfamily, and is responsible for the transport of aspartate across the blood-brain barrier.

ABCE1 is a 21-kDa protein, with a calculated pI of 9.9. It consists of a catalytic active site, a transmembrane region, and an N-terminus region. The catalytic active site is the region of the protein that is responsible for catalyzing the transfer of aspartate across the blood-brain barrier. This site is known to contain a heme moiety, which is thought to play a key role in the regulation of aspartate transport.

The transmembrane region of ABCE1 is responsible for maintaining the stability of the protein and for regulating its expression. This region is known to contain a tyrosine residue, which is thought to play a key role in the regulation of protein stability and localization.

The N-terminus region of ABCE1 is responsible for the interaction with other proteins and for the regulation of protein function. This region is known to contain a variety of conserved domains, including a leucine residue and a glutamic acid residue. These domains are thought to play a key role in the regulation of protein function and stability.

Expression and localization of ABCE1

ABCE1 is expressed in most tissues and cells of the body, with higher levels of expression in the brain. In the brain, ABCE1 is expressed in all cell types, and is particularly high in the prefrontal cortical cortical region. This suggests that ABCE1 plays a crucial role in the regulation of neurotransmitter synthesis and release in the brain, and that its dysfunction may contribute to the development of neurodegenerative diseases.

ABCE1 is also expressed in other tissues and cells of the body, including the heart, the kidneys, and the liver. However, its expression is not as high in these tissues, suggesting that ABCE1 may have different functions in these tissues.

Drugs that target ABCE1

Several drugs that target ABCE1 have been developed and are in use for the treatment of

Protein Name: ATP Binding Cassette Subfamily E Member 1

Functions: Cotranslational quality control factor involved in the No-Go Decay (NGD) pathway (PubMed:21448132). Together with PELO and HBS1L, is required for 48S complex formation from 80S ribosomes and dissociation of vacant 80S ribosomes (PubMed:21448132). Together with PELO and HBS1L, recognizes stalled ribosomes and promotes dissociation of elongation complexes assembled on non-stop mRNAs; this triggers endonucleolytic cleavage of the mRNA, a mechanism to release non-functional ribosomes and to degrade damaged mRNAs as part of the No-Go Decay (NGD) pathway (PubMed:21448132). Plays a role in the regulation of mRNA turnover (By similarity). Plays a role in quality control of translation of mitochondrial outer membrane-localized mRNA (PubMed:29861391). As part of the PINK1-regulated signaling, ubiquitinated by CNOT4 upon mitochondria damage; this modification generates polyubiquitin signals that recruit autophagy receptors to the mitochondrial outer membrane and initiate mitophagy (PubMed:29861391). RNASEL-specific protein inhibitor which antagonizes the binding of 2-5A (5'-phosphorylated 2',5'-linked oligoadenylates) to RNASEL (PubMed:9660177). Negative regulator of the anti-viral effect of the interferon-regulated 2-5A/RNASEL pathway (PubMed:9660177, PubMed:9847332, PubMed:11585831)

The "ABCE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABCE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets